Has Bret Sohn, MD received payments from drug or device companies?

Yes. Drug and device makers reported $447,347 in general payments to Bret Sohn, MD across 819 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bret Sohn, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bret Sohn, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bret Sohn, MD

Rheumatology · Stamford, CTNPI 1982994836

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $332,606 of the $447,347 with a category attached, or 74.4%. 17 manufacturers reported payments, led by UCB, Inc. at 44.8% of the total. 2025 is the largest year on record at $242,081, more than ten times the $243 reported in 2019. Among rheumatology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$447,347in general payments, 2019–2025

Across 819 payments — averaging $546.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

UCB, Inc.$201K
Johnson & Johnson$184K
Amgen$49K
AbbVie$10K
UCB SA$1K
Janssen Scientific Affairs, LLC$1K
plus $2K from 11 others

$12,219in research payments, 2019–2025

Across 3 payments — averaging $4073.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$12K

What the payments were for

Consulting fees$54,85312%
Speaking & faculty fees$332,60674%
Travel & lodging$42,78610%
Food & beverage$16,7344%
Education$3680%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
UCB, Inc.	358	$200,572
Johnson & Johnson	255	$183,554
Amgen(2 entities)	82	$49,360
AbbVie	45	$9,643
UCB SA	2	$1,380
Janssen Scientific Affairs, LLC	4	$1,018
Lilly USA, LLC	15	$468
Pfizer	26	$430
Novartis	7	$342
GSK	11	$217
Aurinia Pharma U.S., Inc.	5	$103
Cardinal Health 110 LLC	1	$100
AstraZeneca	3	$63
Amarin Pharma, Inc.	2	$38
Invivyd Inc	1	$27
Boston Scientific	1	$18
Boehringer Ingelheim	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tremfya$169,071
SIMPONI ARIA$125,279
Bimzelx$122,300
Cimzia$65,086
UPLIZNA$36,481
Rinvoq$8,073
Skyrizi$925
STELARA$850
COSENTYX$110

How this compares

$447,347 in reported general payments places this provider in the 95th percentile of 118 rheumatology providers in Connecticut.

See all rheumatology providers in Connecticut →

Medicare billing

Part B allowed, 2024

$63,789

Medicare patients

295

Services billed

611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	19	$238,377
Taltz AutoinjectorIxekizumab	12	$81,089
Cosentyx Sensoready PenSecukinumab	11	$77,334
Colchicine	52	$3,981
Prednisone	457	$3,139
Leflunomide	54	$2,926
MethotrexateMethotrexate Sodium	90	$2,282
Hydroxychloroquine Sulfate	103	$1,773
Methylprednisolone	65	$812
Allopurinol	95	$461
Diclofenac Sodium	48	$450
Gabapentin	30	$401
Folic Acid	41	$377
Celecoxib	13	$335
Nitro-BidNitroglycerin	14	$313

Paid to pharmacies, not to this prescriber.

Other rheumatology in Stamford

Hana HulinskaStamford$9K
Kenneth MillerDanbury$873K
Robert SchoenGuilford$638K
Fotios KoumpourasNorth Haven$314K
James SeiboldFarmington$300K
Michael SpiegelDanbury$215K
John MagaldiTorrington$157K
Archana SharmaBristol$98K
Richard RoseffDanbury$84K
Beth ValashinasOrange$81K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →